• Publications
  • Influence
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
BACKGROUND Deletion of chromosome 17p (del[17p]) in patients with chronic lymphocytic leukaemia confers very poor prognosis when treated with standard chemo-immunotherapy. Venetoclax is an oralExpand
  • 483
  • 27
  • PDF
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.
We present a phase II, single-arm study evaluating 800 mg daily venetoclax, a highly selective, oral small-molecule B-cell leukemia/lymphoma-2 (BCL2) inhibitor in patients with high-riskExpand
  • 421
  • 15
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
BACKGROUND Selective BCL2 inhibition with venetoclax has substantial activity in patients with relapsed or refractory chronic lymphocytic leukaemia. Combination therapy with rituximab enhancedExpand
  • 197
  • 12
The role of palliative radiation therapy in symptomatic locally advanced gastric cancer.
  • J. Tey, M. Back, +6 authors M. Zhu
  • Medicine
  • International journal of radiation oncology…
  • 1 February 2007
PURPOSE To review the outcome of palliative radiotherapy (RT) alone in patients with symptomatic locally advanced or recurrent gastric cancer. METHODS AND MATERIALS Patients with symptomaticExpand
  • 70
  • 3
A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)
Introduction: BCL-2 has been implicated in hematologic malignancies and associated with drug resistance and poor prognosis in acute myelogenous leukemia (AML). Patients (pts) with relapsed/refractoryExpand
  • 52
  • 2
Phase Ib/2 study of venetoclax with low-dose cytarabine in treatment-naive patients age ≥ 65 with acute myelogenous leukemia.
7007Background: Treatment options for older patients (pts) with acute myelogenous leukemia (AML) unfit for intensive chemotherapy are limited. Expected complete remission rates for low-doseExpand
  • 32
  • 2
Results of a phase 1b study of venetoclax plus decitabine or azacitidine in untreated acute myeloid leukemia patients ≥ 65 years ineligible for standard induction therapy.
7009Background: Venetoclax (VEN) is a potent, orally bioavailable BCL-2 inhibitor with single-agent activity in relapsed/refractory acute myeloid leukemia (AML) patients (pts), displaying synergisticExpand
  • 46
  • 1
The pursuit of balance: An overview of covariate-adaptive randomization techniques in clinical trials.
Randomization is fundamental to the design and conduct of clinical trials. Simple randomization ensures independence among subject treatment assignments and prevents potential selection biases, yetExpand
  • 41
  • 1
Chinese herbal medicine, Jianpi Ligan decoction, improves prognosis of unresectable hepatocellular carcinoma after transarterial chemoembolization: a retrospective study
Objective This study aimed to investigate the efficacy of Jianpi Ligan decoction (JLD) as an adjuvant therapy for patients with unresectable hepatocellular carcinoma (HCC) treated by transarterialExpand
  • 8
  • 1
  • PDF
Is it time for the weighted log-rank test to play a more important role in confirmatory trials?
  • Z. Su, M. Zhu
  • Medicine
  • Contemporary clinical trials communications
  • 18 September 2017
The log-rank test is frequently used to detect a potential treatment effect in randomized clinical trials with time-to-event endpoints. It is asymptotically the most powerful test under theExpand
  • 5
  • 1